Ralf Kuriyel, Senior VP, R&D at REPLIGEN CORP (RGEN), sold 16,000 shares at $191.33 ($3.0M) on 2021-03-10, disclosed to the SEC on 2021-03-12.
Seasonal sale ($3.0M) by Senior VP, R&D — this insider has traded RGEN in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $190.08 | 6,354 | $1.2M | 39.6% |
| 2 | $190.08 | 6,354 | $1.2M | 39.6% |
| 3 | $191.33 | 642 | $123K | 4.0% |
| 4 | $191.33 | 642 | $123K | 4.0% |
| 5 | $192.13 | 1,004 | $193K | 6.3% |
| 6 | $192.13 | 1,004 |
| $193K |
| 6.3% |
| Total | $190.44 avg | 16,000 | $3.0M | 100% |
| Filing → |
| RGEN | SELL | 2024-03-12 | $1.4M | — | Filing → |
| RGEN | SELL | 2022-08-12 | $2.3M | — | Filing → |
| RGEN | SELL | 2021-09-02 | $2.3M | — | Filing → |